Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Canaan Inc. Closes US$72 Million Registered Direct Offering with Brevan Howard, Galaxy Digital, and Weiss Asset Management
-
New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer
-
Skin Clique Debuts Holiday Skin Health Event with Early Savings and Gifting That Puts Confidence First
-
ATEC Mourns Passing of Board Member Jeffrey P. Rydin
-
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meet
-
AB Amber Grid Operating Results for 9 months of 2025
-
Lincoln Tech to Expand Presence in Texas with New Rowlett Campus
-
Central Garden & Pet Strengthens National Logistics Network with New Salt Lake City Facility
-
CHS Foundation and CoBank Partner to Donate $2 Million to Feeding America® Amid Rising Needs at Rural Food Banks
-
Summit Health Physicians Earn National Recognition as 2025 Jersey Choice “Top Doctors”
-
Strategy Overview Named Champion of PitchIT Competition at IT Nation Connect 2025
-
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
-
Changes in Nokia Corporation's own shares
-
H/Advisors Abernathy Named Private Equity Wire’s U.S. PR & Communications Firm of the Year in 2025 for Second Consecutive Year
-
ACCA Re-elects Three North American Members to the Global Accounting Body’s Council
-
Bluum Unveils 17,000 Sq Ft Phoenix Facility
-
RFN's SX-E60: A New Era of Control in Electric Off-Roading Explored at EICMA Roundtable
-
Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
-
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
-
Attorney Share Launches AI Lead Scoring to Help Attorneys Prioritize the Most Promising Case Opportunities
-
Rain Enhancement Technologies Holdco, Inc. Regains Compliance with Nasdaq Listing Requirements
-
FloridaCNAOnline.com Launches Fully Bilingual Program With Enhanced Curriculum for 2025
-
pixiv Announces 2025 Christmas Charity Partnership With Book Santa, a Social Welfare Project Providing Books to Children
-
Scala Data Centers, Lightera, and Nokia conduct the first AccuCore HCF™ (Hollow Core Fiber) test in Latin America
-
DigitalRoute to End the "Usage Monetization Drama" with Major Announcement on November 11
-
MobileFuse Wins Platinum Award at 2025 MarCom Awards for "Broad Banking Prospects" Campaign
-
Long-Term Study Reports Sustained Quality of Life Benefits with the BioProtect Balloon Spacer in Prostate Cancer Radiation Therapy
-
Punchcut Appoints Akshat Srivastava Director of Design Engineering
-
Cineverse to Report Second Quarter FY 2026 Financial Results on Friday, November 14, 2025
-
Bitget Slashes Stock Futures Trading Fees by 90% as Daily Volume Surpasses $300 Million
-
Legrand Acquires Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions
-
Tomorrow Cellars Toasts the Holidays with Alcohol-Removed Wines and Festive Seasonal Offerings For Every Occasion
-
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
PitchBook Expands Credit Research Suite with New CLO Portfolio Holdings Universe
-
HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
-
A2 Biotherapeutics Presents Initial Safety and Efficacy Data from Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in a Patient with NSCLC
-
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
-
Spirit Airlines Reaches Agreements with Pilots and Flight Attendants as it Continues to Advance its Restructuring
-
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
-
Unwrap a Magical Holiday Escape at Four Seasons Resort Orlando at Walt Disney World Resort
-
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducte
-
Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma
-
Kapitale Secures $25M Credit Facility to Empower US Small Businesses
-
James Hardie Announces Participation At Upcoming Investor Conferences and Timing of Second Quarter FY26 Earnings Release & Conference Call
-
Malar Group Announces Strategic Investment In Spendsafe To Transform Financial Literacy For The Next Generation
-
Nexteer Expands India Technical Center to Advance Driveline Validation Capabilities
-
Dragon Shield & Beckett Send First Sleeved TCG Card To the Edge of Space
-
Stewart Strengthens Real Estate Services Portfolio by Announcing its Intent to Acquire Mortgage Contracting Services (MCS)
-
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment
